Oncoinvent ASA Asset Resilience Ratio
Oncoinvent ASA asset resilience ratio. Oncoinvent ASA (ONCIN) has an Asset Resilience Ratio of 80.12% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Oncoinvent ASA fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Oncoinvent ASA (2022–2025)
Asset resilience ratio of Oncoinvent ASA from 2022 to 2025. This chart shows how Oncoinvent ASA's Asset Resilience Ratio has changed over time. Read ONCIN current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Oncoinvent ASA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Oncoinvent ASA.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr65.92 Million | 75.98% |
| Short-term Investments | Nkr3.59 Million | 4.14% |
| Total Liquid Assets | Nkr69.51 Million | 80.12% |
Asset Resilience Insights
- Very High Liquidity: Oncoinvent ASA maintains exceptional liquid asset reserves at 80.12% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Oncoinvent ASA Industry Peers by Asset Resilience Ratio
Compare Oncoinvent ASA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Oncoinvent ASA Asset Resilience Ratio by Year (2022–2025)
Oncoinvent ASA asset resilience ratio by year from 2022 to 2025. The table below shows the annual Asset Resilience Ratio data for Oncoinvent ASA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 86.65% | Nkr177.60 Million ≈ $18.69 Million |
Nkr204.96 Million ≈ $21.57 Million |
+4.70pp |
| 2024-12-31 | 81.95% | Nkr140.16 Million ≈ $14.75 Million |
Nkr171.01 Million ≈ $18.00 Million |
-7.77pp |
| 2023-12-31 | 89.72% | Nkr156.42 Million ≈ $16.46 Million |
Nkr174.34 Million ≈ $18.35 Million |
-0.74pp |
| 2022-12-31 | 90.46% | Nkr150.80 Million ≈ $15.87 Million |
Nkr166.71 Million ≈ $17.54 Million |
-- |
About Oncoinvent ASA
Oncoinvent ASA, a clinical stage company, develops radiopharmaceutical therapies against cancer. Its lead product candidate is Radspherin, an alpha-radiation therapy candidate for treating cancer that have spread to body cavities, including peritoneum in two phase 1/2a trials and one randomized phase 2 trial. The company is based in Oslo, Norway.